Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant oxaliplatin-based therapy (TNT) before (induction) and after (consolidation) chemoradiation for advanced rectal cancer: MRI correlation on complete response and outcome.
Authors
Putao Cen
The University of Texas Health Science Center at Houston (UTHealth Houston) McGovern Medical School, Houston, TX;
Putao Cen , Kok Hoe Chan , Jeffrey Van Eps , Julie Haewon Rowe , Curtis Jackson Wray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 165)
DOI
10.1200/JCO.2023.41.4_suppl.165
Abstract #
165
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Single-arm confirmatory trial of total neoadjuvant therapy and watch-and-wait strategy for patients with low rectal cancer: Japan Clinical Oncology Group study (JCOG2010, TOWARd study).
First Author: Shunsuke Tsukamoto
Poster
2020 Gastrointestinal Cancers Symposium
An assessment of dose intensity of the TNT approach on outcomes in locally advanced rectal cancer.
First Author: Ashley Elizabeth Glode
Poster
2022 ASCO Annual Meeting
PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer.
First Author: Aiwen WU
Poster
2022 ASCO Annual Meeting
Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer.
First Author: Aiwen WU